CytomX Therapeutics (CTMX) Other Non-Current Liabilities (2014 - 2026)

CytomX Therapeutics has reported Other Non-Current Liabilities for 10 years, with the latest figure at $4.4 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 5.63% year-over-year to $4.4 million; the trailing twelve-month figure through Mar 2026 stood at $4.4 million (up 5.63% YoY), and the FY2025 full-year result was $4.4 million, up 5.78% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $4.4 million, up from $4.4 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $4.4 million in Q1 2026, with the low at $216000.0 in Q2 2023.
• Historically, Other Non-Current Liabilities has averaged $3.7 million across 4 years, with a median of $4.1 million in 2024.
• Annual changes were most pronounced in 2024 — Other Non-Current Liabilities surged 1748.61% — and 2026, when it gained 5.63%.
• CytomX Therapeutics' Other Non-Current Liabilities stood at $3.9 million in 2023, then grew by 5.7% to $4.1 million in 2024, then climbed by 5.78% to $4.4 million in 2025, then gained by 1.36% to $4.4 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $4.4 million (Q1 2026), $4.4 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.